E-Mail
Scientists at UC San Francisco have detected 109 chemicals in a study of pregnant women, including 55 chemicals never before reported in people and 42 mystery chemicals, whose sources and uses are unknown.
The chemicals most likely come from consumer products or other industrial sources. They were found both in the blood of pregnant women, as well as their newborn children, suggesting they are traveling through the mother s placenta.
The study will be published March 17, 2021, in
Environmental Science & Technology. These chemicals have probably been in people for quite some time, but our technology is now helping us to identify more of them, said Tracey J. Woodruff, PhD, a professor of obstetrics, gynecology and reproductive sciences at UCSF.
Date Time
Study Finds Evidence of 55 Chemicals Never Before Reported in People
Scientists at UC San Francisco have detected 109 chemicals in a study of pregnant women, including 55 chemicals never before reported in people and 42 “mystery chemicals,” whose sources and uses are unknown.
The chemicals most likely come from consumer products or other industrial sources. They were found both in the blood of pregnant women, as well as their newborn children, suggesting they are traveling through the mother’s placenta.
The study was published March 17 in Environmental Science & Technology.
“These chemicals have probably been in people for quite some time, but our technology is now helping us to identify more of them,” said Tracey J. Woodruff, PhD, a professor of obstetrics, gynecology and reproductive sciences at UCSF.
Winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition Announced
Share Article ROCKVILLE, Md. (PRWEB) February 22, 2021 Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition, a first of its kind program for female entrepreneurs starting oncology companies.
Privo Technologies has developed a nano-engineered platform for redesigning the mechanism of action of potent cancer medicines. The company was selected from among 47 female-led oncology start-ups following rigorous review and evaluation by three blue ribbon committees. As a result, Privo Technologies has received investment totaling $900,000 $300,000 from AIM-HI and matching investments from two supporters of the Women’s Venture Competition.
Winner of the AIM-HI Accelerator Fund s Inaugural Women s Venture Competition Announced benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.